Methods and compositions for treating melanoma
US-2024424002-A1 · Dec 26, 2024 · US
Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
US9889088B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9889088-B2 |
| Application number | US-201113010958-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 21, 2011 |
| Priority date | Jan 21, 2010 |
| Publication date | Feb 13, 2018 |
| Grant date | Feb 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline intraocular pressure for at least eight (8) hours.
First claim
Opening claim text (preview).
What is claimed: 1. A method of lowering intraocular pressure, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole or a salt thereof, by direct injection to an affected eye of a patient once or twice per day, such that the affected eye has an intraocular pressure less than the baseline intraocular pressure for at least six (6) hours. 2. The method of claim 1 , wherein the affected eye maintains an intraocular pressure less than the baseline intraocular pressure for at least eight (8) hours. 3. The method of claim 1 , wherein the affected eye maintains an intraocular pressure less than the baseline intraocular pressure for at least ten (10) hours. 4. The method of claim 1 , wherein the composition comprises 0.01% to 5% by weight, 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole or a salt thereof. 5. The method of claim 1 , wherein the composition comprises 0.15% to 1% by weight, 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole or a salt thereof. 6. The method of claim 1 , wherein the composition further comprises from 0.001% to 1% by weight of a preservative. 7. The method of claim 1 , wherein the composition further comprises from 0.01% to 0.5% by weight of a preservative. 8. The method of claim 1 , wherein the composition further comprises from 0.001% to 0.01% by weight of a preservative. 9. The method of claim 1 , wherein the composition further comprises from 0.01% to 1% by weight of a co-solvent. 10. The method of claim 1 , wherein the composition further comprises from 0.01% to 2% by weight of a viscosity building agent. 11. The method of claim 1 wherein 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole is undetectable in the systemic circulation subsequent to administration. 12. The method of claim 1 , wherein 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole is maintained in the aqueous humor for at least ten (10) hours. 13. The method of claim 1 , wherein said composition is administered once a day.
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Antiglaucoma agents or miotics · CPC title
- A61K31/4184Primary
condensed with carbocyclic rings, e.g. benzimidazoles · CPC title
- A61K9/0048Primary
Eye, e.g. artificial tears · CPC title
Ophthalmic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9889088B2 cover?
- The present invention provides a method of lowering intraocular pressure which comprises administering a therapeutically effective amount of a pharmaceutical composition comprising 4-bromo-5-(2-imidazolin-2-ylamino)benzimidazole, or a salt thereof to the affected eye of a patient, as a single dose, wherein the affected eye has an intraocular pressure less than the baseline intraocular pressure …
- Who is the assignee on this patent?
- Dibas Mohammed I, Gil Daniel W, Donello John E, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4184. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).